Profile | GDS2987 / GI_4507824-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 16.9 | 40 |
GSM215253 | HMVEC_vehicle_rep3 | 10.4 | 34 |
GSM215254 | HMVEC_atorvastatin_rep1 | 7.6 | 21 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | 4.3 | 11 |
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | 3.9 | 8 |
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | 24 | 37 |
GSM215294 | HMVEC_SLx2119_rep1 | 36.8 | 67 |
GSM215295 | HMVEC_SLx2119_rep2 | 26.3 | 47 |
GSM215296 | HMVEC_SLx2119_rep3 | 24 | 38 |
GSM215297 | PASMC_vehicle_rep1 | 66.3 | 66 |
GSM215298 | PASMC_vehicle_rep2 | 53.5 | 61 |
GSM215310 | PASMC_vehicle_rep3 | 28.6 | 42 |
GSM215311 | PASMC_atorvastatin_rep1 | 44 | 59 |
GSM215312 | PASMC_atorvastatin_rep2 | 9.4 | 15 |
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 22.3 | 36 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 9.9 | 20 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | 29.9 | 46 |
GSM215327 | PASMC_SLx2119_rep1 | 36.9 | 53 |
GSM215328 | PASMC_SLx2119_rep2 | 35.6 | 53 |
GSM215329 | PASMC_SLx2119_rep3 | 7.9 | 16 |
GSM215330 | Fibroblasts_vehicle_rep1 | 128.6 | 77 |
GSM215331 | Fibroblasts_vehicle_rep2 | 159.4 | 79 |
GSM215332 | Fibroblasts_vehicle_rep3 | 109.7 | 76 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 80.3 | 73 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 105.2 | 75 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 123.3 | 77 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 78.1 | 73 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 126.6 | 78 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 73.6 | 72 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 73.2 | 72 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 57.9 | 70 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 72.4 | 72 |